| Literature DB >> 35692675 |
Takashi Ueda1, Hideki Mori2, Tatsuya Sekiguchi3, Yusuke Mishima1, Masaya Sano1, Erika Teramura1, Ryutaro Fujimoto1, Motoki Kaneko1, Hirohiko Nakae1, Mia Fujisawa1, Masashi Matsushima1, Hidekazu Suzuki1.
Abstract
Transarterial embolization (TAE) is performed in patients with colonic diverticular bleeding after difficult endoscopic hemostasis or rebleeding. A total of 375 patients with hematochezia at our hospital from 1 April 2016 to 31 March 2020 were retrospectively analysed. Firstly, we compared the group in which hemostasis was achieved by endoscopy alone with the group that eventually underwent TAE. Secondly, we compared the group in which hemostasis was achieved by endoscopy alone, with the group switched to TAE after endoscopic hemostasis failed. The group that eventually underwent TAE had a higher shock index and lower Alb and PT% than the endoscopic hemostasis group. The shock index was correlated with Alb and PT%. When the cut-off value for the shock index was defined as more than 0.740, an OR of 9.500, a positive predictive value (PPV) of 40.0%, a negative predictive value (NPV) of 93.4%, and an accuracy of 80.3% were obtained for predicting a switch to TAE treatment. The greatest risk for TAE was the presence of shock and extravasation on contrast-enhanced CT. A switch to TAE treatment was likely when the shock index was more than 0.740. TAE should be considered in cases with a high shock index and showing extravasation on contrast-enhanced CT.Entities:
Keywords: TAE; diverticular bleeding; extravasation on contrast-enhanced CT examination; shock index
Year: 2021 PMID: 35692675 PMCID: PMC9130068 DOI: 10.3164/jcbn.21-123
Source DB: PubMed Journal: J Clin Biochem Nutr ISSN: 0912-0009 Impact factor: 3.179
Fig. 1.Flow diagram of this study.
Clinical characteristics and risk of the group of endoscopic hemostasis and the group of TAE hemostasis
| Endoscopic | TAE | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| Total number, | 69 | 12 | |||
| Age [years (mean ± SD)] | 71.87 ± 10.49 | 75.4 ± 11.5 | 0.296† | 1.034 (0.971–1.101) | |
| Sex, | 48 (69.6) | 10 (83.3) | 0.273‡ | 0.457 (0.092–2.27) | |
| Smoking, | 23 (33.3) | 6 (50.0) | 0.214‡ | 0.500 (0.145–1.723) | |
| Drinking, | 23 (33.3) | 4 (33.3) | 0.620‡ | 1.00 (0.272–3.671) | |
| BMI [kg/m2 (mean ± SD)] | 24.23 ± 4.48 | 21.4 ± 2.6 | 0.040† | 0.784 (0.621–0.989) | 0.734 (0.513–1.053) |
| History of diverticular bleeding, | 21 (30.4) | 4 (33.3) | 0.542‡ | 0.875 (0.237–3.227) | |
| Medical history, | |||||
| Cerebral infarction | 8 (11.6) | 2 (16.7) | 0.457‡ | 0.656 (0.121–3.545) | |
| Heart disease | 22 (31.9) | 7 (58.3) | 0.077‡ | 0.334 (0.095–1.172) | |
| Hypertension | 40 (60.0) | 6 (50.0) | 0.607‡ | 1.379 (0.404–4.711) | |
| Hyperlipidemia | 17 (24.6) | 4 (33.3) | 0.346‡ | 0.615 (0.164–2.314) | |
| Diabetes | 16 (23.1) | 0 (0.0) | 0.335‡ | 0.604 (0.161–2.269) | |
| Asthma | 3 (4.3) | 0 (0.0) | 0.760‡ | N/A | |
| Kidney disease | 5 (7.2) | 0 (0.0) | 0.629‡ | N/A | |
| Contrast media allergy | 0 (0.0) | 0 (0.0) | N/A | N/A | |
| Drug, | |||||
| Antiplatelet | 12 (17.4) | 5 (41.7) | 0.070‡ | 0.295 (0.08–1.088) | |
| Anticoagulant | 16 (23.2) | 4 (33.3) | 0.335‡ | 0.604 (0.161–2.269) | |
| Blood test | |||||
| Hb [g/dl (mean ± SD)] | 11.32 ± 2.71 | 9.89 ± 2.70 | 0.099† | 0.820 (0.646–1.040) | |
| PLT [×104/μl (mean ± SD)] | 21.48 ± 6.77 | 23.29 ± 19.84 | 0.770† | 1.016 (0.963–1.070) | |
| Alb [g/dl (mean ± SD)] | 3.66 ± 0.47 | 2.84 ± 0.55 | 0.000† | 0.043 (0.008–0.217) | 0.057 (0.009–0.349) |
| PT% [% (mean ± SD)] | 84.72 ± 20.66 | 65.67 ± 28.94 | 0.056† | 0.971 (0.948–0.994) | 0.974 (0.937–1.014) |
| Extravasation by contrast-enhanced CT, | 19 (31.7) | 12 (100) | 0.000‡ | N/A | |
| The bleeding site is the right hemicolon, | 39 (56.5) | 9 (75.0) | 0.190‡ | 0.433 (0.108–1.741) | |
| Shock index (mean ± SD) | 0.62 ± 0.20 | 0.84 ± 0.22 | 0.001† | 44.812 (3.203–626.895) | 4.691 (0.149–147.544) |
Shock index measurement, blood test, and contrast-enhanced CT examination are performed immediately after the visit. TAE, transarterial embolization; BMI, body mass Index; Hb, hemoglobin; Alb, albumin; PT%, prothrombin time%; CT, computed tomography; N/A, not applicable. †Student’s t test; ‡Fisher’s exact test.
Fig. 2.(A) is showed a linear analysis to examine the relationship between Alb, PT%, and the shock index. (B) is showed that Kaleidagraph is used to show the correlation between anticoagulants and coagulants and PT%. PT% is significantly correlated with anticoagulants.
Fig. 3.This is showed ROC curves based on the shock index. When the cut-off value for the shock index was defined as more than 0.740, an OR of 9.500 (95% CI, 2.458 to 36.721), a positive predictive value (PPV) of 40.0%, a negative predictive value (NPV) of 93.4%, and an accuracy of 80.3% were obtained for predicting the occurrence of TAE treatment.
Clinical characteristics and risk of the group of endoscopic hemostasis and the group of switched to TAE after endoscopic hemostasis failure
| Endoscopic | Switch to TAE | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| Total number, | 69 | 5 | |||
| Age [years (mean ± SD)] | 71.87 ± 10.49 | 71.2 ± 4.26 | 0.889† | 0.994 (0.910–1.085) | |
| Sex, | 48 (69.6) | 5 (100) | 0.178‡ | N/A | |
| Smoking, | 23 (33.3) | 4 (80.0) | 0.056‡ | 0.125 (0.013–1.183) | |
| Drinking, | 23 (33.3) | 2 (40.0.) | 0.553‡ | 0.750 (0.117–4.808) | |
| BMI [kg/m2 (mean ± SD)] | 24.23 ± 4.48 | 21.8 ± 2.31 | 0.241† | 0.819 (0.589–1.137) | |
| History of diverticular bleeding, | 22 (31.9) | 3 (60.0) | 0.190‡ | 0.292 (0.045–1.876) | |
| Medical history, | |||||
| Cerebral infarction | 8 (11.6) | 2 (40.0) | 0.132‡ | 0.197 (0.028–1.362) | |
| Heart disease | 22 (31.9) | 2 (40.0) | 0.525‡ | 0.702 (0.109–4.508) | |
| Hypertension | 40 (60.0) | 3 (60.0) | 0.653‡ | 0.608 (0.404–4.711) | |
| Hyperlipidemia | 17 (24.6) | 1 (20.0) | 0.670‡ | 1.231 (0.128–11.816) | |
| Diabetes | 16 (23.1) | 2 (40.0) | 0.352‡ | 0.453 (0.069–2.951) | |
| Asthma | 3 (4.3) | 0 (0.0) | 0.808‡ | N/A | |
| Kidney disease | 5 (7.2) | 0 (0.0) | 0.698‡ | N/A | |
| Contrast media allergy | 0 (0.0) | 0 (0.0) | N/A | N/A | |
| Drug, | |||||
| Antiplatelet | 12 (17.4) | 3 (60.0) | 0.054‡ | 0.140 (0.021–0.933) | 0.094 (0.005–1.862) |
| Anticoagulant | 16 (23.2) | 2 (40.0) | 0.352‡ | 0.453 (0.069–2.951) | |
| Blood test | |||||
| Hb [g/dl (mean ± SD)] | 11.32 ± 2.71 | 10.2 ± 3.47 | 0.390† | 0.862 (0.617–1.205) | |
| PLT [×104/μl (mean ± SD)] | 21.48 ± 6.77 | 18.64 ± 5.68 | 0.369† | 0.935 (0.808–1.081) | |
| Alb [g/dl (mean ± SD)] | 3.66 ± 0.47 | 3.08 ± 0.466 | 0.012† | 0.079 (0.009–0.663) | 0.087 (0.007–1.062) |
| PT% [% (mean ± SD)] | 84.72 ± 20.66 | 69.0 ± 35.709 | 0.431† | 0.976 (0.945–1.009) | |
| Extravasation by contrast-enhanced CT, | 19 (31.7) | 5 (100) | 0.002‡ | N/A | |
| The bleeding site is the right hemicolon, | 39 (56.5) | 4 (80.0) | 0.297‡ | 0.325 (0.035–3.060) | |
| Shock index (mean ± SD) | 0.62 ± 0.20 | 0.905 ± 0.257 | 0.004† | 56.268 (2.208–1,433.698) | 28.972 (0.806–1,041.367) |
Shock index measurement, blood test, and contrast-enhanced CT examination are performed immediately after the visit. TAE, transarterial embolization; BMI, body mass Index; Hb, hemoglobin; Alb, albumin; PT%, prothrombin time%; CT, computed tomography; N/A, not applicable. †Student’s t test; ‡Fisher’s exact test.
Background of endoscopic hemostasis failure
| Case | Sex | Age | Areas with extravascular | Reasons of endoscopic | Antithrombotics | Medical history |
|---|---|---|---|---|---|---|
| 1 | Male | 60s | A/C | Multiple diverticula | Warfarin | HT |
| 2 | Male | 70s | A/C | Multiple diverticula | Aspirin | HT |
| 3 | Male | 60s | A/C | Multiple diverticula | Aspirin | HT |
| 4 | Male | 70s | S/C | Multiple diverticula | None | None |
| 5 | Male | 70s | A/C | Multiple diverticula | Warfarin | Cerebral infarction |
A/C, ascending colon; S/C, sigmoid colon; HT, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease.